Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trialJacob Elkins, Mitchell S.V. Elkind, Aneesh B. Singhal et al.|The Lancet Neurology|2017Cited by 213
Five years of ocrelizumab in relapsing multiple sclerosisStephen L. Hauser, Xavier Montalbán, Ludwig Kappos et al.|Neurology|2020Cited by 159